Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03269994 · ClinicalTrials.gov registry record · Phase 3
Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
A Phase 3 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 967
- Enrollment target
NCT03269994: Completed Phase 3 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03269994 is a Phase 3 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 967 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03269994, a Phase 3 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 967 participants
- Enrollment target
Study Summary
The purpose of this study is to figure out which commonly used antibiotic, cefoxitin or piperacillin-tazobactam, is better at decreasing the rate of surgical site infections after pancreatoduodenectomy.
Interventions
- DRUG Cefoxitin
- DRUG Piperacillin-tazobactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 967 participants |
| Start Date | 2017-11-21 |
| Est. Completion | 2025-01-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03269994
The ClinicalTrials.gov registry entry for NCT03269994 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 967 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cefoxitin is the first listed.
NCT03269994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03269994 about?
NCT03269994 is a clinical study titled "Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?". The purpose of this study is to figure out which commonly used antibiotic, cefoxitin or piperacillin-tazobactam, is better at decreasing the rate of surgical site infections after pancreatoduodenectomy.
What is the current status of trial NCT03269994?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 967 participants. The study started on 2017-11-21. Estimated completion is 2025-01-28.
What interventions are being tested in trial NCT03269994?
The interventions under investigation include: Cefoxitin (DRUG), Piperacillin-tazobactam (DRUG).
Who is sponsoring clinical trial NCT03269994?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.